GLP-1 Agonists: Weight Loss, Multi-System Health Benefits

Sofia A. Petrova
Clinical Nutrition & Metabolism Department, Baltic Institute of Health Sciences, Latvia

*Corresponding Authors**

Sofia A. Petrova
Clinical Nutrition & Metabolism Department, Baltic Institute of Health Sciences, Latvia
E-mail: petrova.sa@gmail.com

Received: 01-Apr-2025, Manuscript No. jdm-25-38678, **Editor assigned:** 03-Apr-2025, PreQC No. jdm-25-38678(PQ), **Reviewed:** 17-Apr-2025, QC No. jdm-25-38678, **Revised:** 22-Apr-2025, Manuscript No. jdm-25-38678(R), **Published Date:** 29-Apr-2025, DOI: 10.35248/2155-6156. 10001225

Introduction

Semaglutide, administered once-weekly, has demonstrated significant efficacy in promoting substantial weight loss in adults who are overweight or obese. This research positions semaglutide as a powerful therapeutic option extending beyond its established role in type 2 diabetes management, marking a significant step forward in pharmacological approaches to obesity. [1]

Another notable advancement comes from trials demonstrating tirzepatide's superior effectiveness when compared to insulin glargine in managing type 2 diabetes. This agent notably reduces both HbA1c levels and body weight in patients with high cardiovascular risk, showcasing a distinct advantage due to its dual GLP-1 and GIP agonism, which offers enhanced glycemic control and weight management capabilities. [2]

A comprehensive meta-analysis has confirmed that GLP-1 receptor agonists broadly contribute to significantly reducing major adverse cardiovascular events and improving renal outcomes in individuals living with type 2 diabetes. These findings highlight the benefits of these medications beyond just glucose regulation, emphasizing their critical role in comprehensive patient care strategies. [3]

The introduction of oral semaglutide, the first oral GLP-1 receptor agonist, was a pivotal moment, as evidenced by the PIONEER 6 trial. This study established the non-inferiority of oral semaglutide to placebo regarding cardiovascular safety in high-risk type 2 diabetes patients, thereby supporting the broader utility of an oral formulation for enhanced patient accessibility and convenience. [4]

Furthermore, studies have reinforced liraglutide's effectiveness not only for weight loss but also for improving body composition and various cardiometabolic risk factors in individuals battling obesity. This particular research underscores the sustained advantages of GLP-1 RAs within broader weight management frameworks, indicating their utility extends far beyond just diabetic populations. [5]

A detailed review provides an extensive overview of the complex, multifaceted mechanisms through which GLP-1 receptor agonists operate. It meticulously explains their observed efficacy in areas such as glycemic control, facilitating weight loss, and providing significant cardiovascular protection, while also outlining potential avenues for future therapeutic advancements. [6]

Research has also explored the potential of GLP-1 receptor agonists in treating non-alcoholic fatty liver disease (NAFLD). A meta-analysis indicates beneficial effects on liver fat content and inflammation, suggesting a promising and novel therapeutic pathway for managing this increasingly prevalent liver condition. [7]

The STEP-HFpEF trial brought to light that semaglutide significantly alleviates heart failure-related symptoms and markedly improves physical function and overall quality of life in patients diagnosed with heart failure with preserved ejection fraction alongside obesity. These results open up promising new avenues for effectively managing this particularly challenging clinical condition. [8]

Adding to their wide array of benefits, a meta-analysis specifically highlighted the renoprotective effects of GLP-1 receptor agonists in patients contending with type 2 diabetes and chronic kidney disease. The evidence points to reductions in albuminuria and a deceleration in the progression of kidney disease, solidifying their importance in comprehensive multi-organ complication management. [9]

Finally, real-world data, compiled through a systematic review and meta-analysis, has thoroughly validated both the effectiveness and safety of GLP-1 receptor agonists in the practical management of type 2 diabetes outside of highly controlled trial environments. This confirms their consistent benefits in achieving glycemic control and sustained weight reduction in everyday clinical practice. [10]

Description

GLP-1 receptor agonists (GLP-1 RAs) have fundamentally transformed the approach to managing complex metabolic and cardiovascular diseases. These innovative therapeutic agents are widely recognized for their extensive benefits, which significantly extend beyond their initial applications in type 2 diabetes. Their core mechanism of action involves stimulating glucose-dependent insulin secretion, suppressing glucagon release, and crucially, promoting substantial weight loss by enhancing satiety and slowing gastric emptying. This multifaceted physiological impact allows them to address not only glycemic control but also vital comorbidities such as obesity and cardiovascular risks, thereby offering a more integrated and effective approach to comprehensive patient management.

The clinical efficacy of specific GLP-1 RAs, like semaglutide, has been notably demonstrated in promoting substantial weight loss in adults with overweight or obesity, solidifying its role as a powerful treatment option beyond type 2 diabetes. Liraglutide further reinforces these benefits, consistently showing effectiveness in reducing weight, improving body composition, and positively modulating various cardiometabolic risk factors in individuals with obesity. These findings collectively highlight the sustained advantages of GLP-1 RAs as integral components of comprehensive weight management strategies, applicable even to non-diabetic populations.

Cite this article: Petrova SA,(2025) GLP-1 Agonists: Weight Loss, Multi-System Health Benefits. J Diabetes Metab 16: 1225. DOI: 10.35248/2155-6156.10001225

In the context of type 2 diabetes, novel agents such as tirzepatide, a dual GLP-1 and GIP agonist, have proven superior to conventional insulin glargine in managing the condition. Tirzepatide effectively reduces both HbA1c levels and body weight, particularly in patients at high cardiovascular risk, showcasing a significant advantage in glycemic control and weight management. Additionally, the development of oral semaglutide, the first oral GLP-1 receptor agonist, marks a pivotal advancement, demonstrating non-inferiority for cardiovascular safety in high-risk patients and greatly enhancing patient convenience and accessibility.

Beyond their direct metabolic impacts, GLP-1 RAs have garnered substantial evidence for their robust protective roles in cardiovascular and renal health. Comprehensive meta-analyses consistently confirm that these agents significantly reduce the incidence of major adverse cardiovascular events in patients with type 2 diabetes. Furthermore, a growing body of evidence strongly supports their renoprotective effects, manifesting as measurable reductions in albuminuria and a tangible slowing of the progression of chronic kidney disease. These crucial findings underscore their importance in mitigating multi-organ complications and managing the systemic effects of diabetes.

The therapeutic scope of GLP-1 RAs continues its dynamic expansion into novel and exciting clinical domains. Emerging data, for instance, strongly suggests beneficial effects on liver fat content and inflammation in non-alcoholic fatty liver disease (NAFLD), presenting a highly promising new therapeutic avenue. Semaglutide has also demonstrated significant utility by improving heart failure-related symptoms and enhancing physical function and quality of life in obese patients with heart failure with preserved ejection fraction. Such advancements, coupled with real-world data validating their sustained effectiveness and safety, solidify the indispensable status of GLP-1 RAs in contemporary medicine.

Conclusion

Recent studies highlight the significant efficacy of once-weekly semaglutide in promoting substantial weight loss in adults with overweight or obesity, establishing it as a potent treatment beyond type 2 diabetes [1]. Tirzepatide also demonstrates superior efficacy over insulin glargine in managing type 2 diabetes, notably reducing HbA1c and body weight in high cardiovascular risk patients due to its dual GLP-1 and GIP agonism [2]. GLP-1 receptor agonists (GLP-1 RAs) generally reduce major adverse cardiovascular events and improve renal outcomes in type 2 diabetes [3, 9]. The PIONEER 6 trial showed oral semaglutide's cardiovascular safety, enhancing accessibility [4]. Liraglutide reinforces the effectiveness of GLP-1 RAs for weight loss, body composition, and cardiometabolic risk factors in individuals with obesity [5]. A thorough review clarifies the multifaceted mechanisms of GLP-1 RAs, explaining their efficacy in glycemic control, weight loss, and cardiovascular protection [6]. Furthermore, GLP-1 RAs show beneficial effects on liver fat content and inflammation in non-alcoholic fatty liver disease (NAFLD) [7]. Semaglutide also significantly reduces heart failure-related symptoms and improves physical function in patients with heart failure with preserved ejection fraction and obesity [8]. Real-world data validates GLP-1 RAs' sustained benefits in glycemic control and weight reduction in routine clinical practice [10].

References

1. John PHW, Rachel LB, Salvatore C. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002.
2. Anders F, Bente B, Alain D. Tirzepatide versus insulin glargine in type 2 diabetes and high cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398:101-116.
3. Naveed S, Paul W, Theodosios DF. Cardiovascular and Renal Outcomes With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Care. 2021;44:257-269.
4. Mansoor H, Stephen KB, Merete D. Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;381:841-851.
5. Donna MR, W Timothy G, Jian W. Effect of Liraglutide on Weight Loss, Body Composition, and Cardiometabolic Risk Factors in Patients with Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial. Obes Sci Pract. 2020;6:162-172.
6. André JS, Luc FG, Lawrence AL. GLP-1 receptor agonists: mechanisms of action and clinical implications. Exp Clin Endocrinol Diabetes. 2022;130:67-78.
7. Jing Y, Pengfei Z, Yan L. GLP-1 receptor agonists for non-alcoholic fatty liver disease: a meta-analysis. Front Endocrinol (Lausanne). 2022;13:1082530.
8. Mikhail NK, Steen ZA, Barry A. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389:1121-1134.
9. Xin Z, Baoqi Z, Zhen S. GLP-1 receptor agonists and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:1062973.
10. Jun G, Shuo J, Yan W. Real-world effectiveness and safety of GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis. BMC Endocr Disord. 2023;23:164.

Cite this article: Petrova SA,(2025) GLP-1 Agonists: Weight Loss, Multi-System Health Benefits. J Diabetes Metab 16: 1225. DOI: 10.35248/2155-6156.10001225